Beta-defensin 112

Also known as: Beta-defensin 12, Defensin, beta 112, DEFB112, Q30KQ8

**Mechanism of Action** Beta-defensin 112 (DEFB112) is a predicted member of the beta-defensin family, a group of cationic antimicrobial peptides. Its proposed mechanism involves disruption of microbial membranes via electrostatic interactions with negatively charged bacterial phospholipids, leading to pore formation, membrane permeabilization, and cell lysis. This activity is typical of defensins, which also exhibit immunomodulatory properties, though specific functional data for DEFB112 remain uncharacterized. **Key Research Findings** No peer-reviewed studies or PubMed-indexed publications currently exist for Beta-defensin 112. Its classification as "EXPERIMENTAL" indicates that its sequence (UniProt Q30KQ8) has been identified through genomic or computational predictions, but functional validation—including antibacterial efficacy, target specificity, or in vivo activity—has not been experimentally confirmed. The absence of research data precludes any assessment of potency, spectrum, or safety. **Clinical Relevance** Without experimental evidence, Beta-defensin 112 has no established clinical relevance. Its potential as an antimicrobial agent remains hypothetical, and no therapeutic applications, diagnostic uses, or biomarker roles have been investigated. Further studies are required to determine if it possesses biological activity comparable to other beta-defensins. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Frequently asked questions

Related peptides